Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$5.17
+7.5%
$4.18
$1.80
$20.83
$20.42M-0.791.10 million shs153,549 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$12.50
$13.24
$1.27
$15.85
$20.08M1.212,097 shs1,390 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.72
+4.2%
$0.82
$0.65
$7.50
$5.14M0.252.08 million shs76,321 shs
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$1.16
-3.3%
$1.16
$0.85
$4.30
$18.25M1.78231,238 shs753,325 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
+1.91%+8.58%+8.09%+13.44%+1,298.26%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00%-1.96%-8.09%-3.85%+756.16%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-1.38%+0.03%-13.52%-49.93%-88.52%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-4.76%-13.04%+30.63%-35.14%-46.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cingulate Inc. stock logo
CING
Cingulate
3.18 of 5 stars
3.55.00.00.02.90.80.6
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.7891 of 5 stars
0.05.00.00.00.01.70.6
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
1.4396 of 5 stars
0.05.00.00.02.21.70.6
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
2.9445 of 5 stars
3.53.00.00.03.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cingulate Inc. stock logo
CING
Cingulate
3.00
Buy$26.00402.90% Upside
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
0.00
N/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3.00
Buy$6.25438.79% Upside

Current Analyst Ratings Breakdown

Latest KTTA, FNCH, VYNE, and CING Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $61.00
5/19/2025
Cingulate Inc. stock logo
CING
Cingulate
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$12.00 ➝ $11.00
4/25/2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.75 ➝ $4.50
4/21/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$75.00 ➝ $60.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/A$2.32 per shareN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/A$10.60 per shareN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$500K35.29N/AN/A$3.53 per share0.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cingulate Inc. stock logo
CING
Cingulate
-$15.55M-$8.480.00N/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$13.90M-$10.600.00N/AN/A-88.14%-81.21%8/12/2025 (Estimated)
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$39.83M-$0.990.00N/AN/A-6,974.55%-71.89%-58.94%8/13/2025 (Estimated)

Latest KTTA, FNCH, VYNE, and CING Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.24N/AN/AN/A$0.15 millionN/A
8/12/2025Q2 2025
Cingulate Inc. stock logo
CING
Cingulate
-$0.82N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A-$1.61N/A-$1.61N/AN/A
5/8/2025Q1 2025
Cingulate Inc. stock logo
CING
Cingulate
-$1.00-$1.04-$0.04-$1.04N/AN/A
5/8/2025Q1 2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cingulate Inc. stock logo
CING
Cingulate
0.16
1.87
1.87
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A
3.84
3.84
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/A
4.47
4.47

Institutional Ownership

CompanyInstitutional Ownership
Cingulate Inc. stock logo
CING
Cingulate
41.31%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
23.92%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
83.78%

Insider Ownership

CompanyInsider Ownership
Cingulate Inc. stock logo
CING
Cingulate
5.27%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
44.90%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
16.30%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cingulate Inc. stock logo
CING
Cingulate
204.25 million4.02 millionNot Optionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
37.44 million6.23 millionNot Optionable
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3015.21 million14.48 millionNot Optionable

Recent News About These Companies

VYNE Therapeutics Provides Update on VYN202 Program

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cingulate stock logo

Cingulate NASDAQ:CING

$5.17 +0.36 (+7.48%)
Closing price 04:00 PM Eastern
Extended Trading
$5.18 +0.01 (+0.29%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$12.50 0.00 (0.00%)
As of 01:37 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Pasithea Therapeutics stock logo

Pasithea Therapeutics NASDAQ:KTTA

$0.72 +0.03 (+4.20%)
Closing price 03:59 PM Eastern
Extended Trading
$0.72 +0.00 (+0.28%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

VYNE Therapeutics stock logo

VYNE Therapeutics NASDAQ:VYNE

$1.16 -0.04 (-3.33%)
Closing price 04:00 PM Eastern
Extended Trading
$1.18 +0.03 (+2.16%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.